
**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the Quarter Ended March 31, 2026

Commission File Number 1-14840

AMDOCS LIMITED

Hirzel House, Smith Street,
St. Peter Port, Island of Guernsey, GY1 2NG

Amdocs, Inc.
625 Maryville Centre Drive, Suite 200 Saint Louis, Missouri 63141
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

FORM 20-F FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

YES NO

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

AMDOCS LIMITED

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

FOR THE QUARTER ENDED MARCH 31,
2026

INDEX

| | |
|--|----|
| PART I FINANCIAL INFORMATION | 3 |
| Item 1. Financial Statements | 3 |
| Unaudited Consolidated Financial Statements | |
| Consolidated Balance Sheets | 3 |
| Consolidated Statements of Income | 4 |
| Consolidated Statements of Comprehensive Income | 5 |
| Consolidated Statements of Changes in Equity | 6 |
| Consolidated Statements of Cash Flows | 8 |
| Notes to Unaudited Consolidated Financial Statements | 9 |
| Item 2. Operating and Financial Review and Prospects | 21 |
| PART II OTHER INFORMATION | 30 |
| Item 1. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities | 30 |
| Item 2. Reports on Form 6-K | 30 |
| SIGNATURES | 31 |

This report on Form 6-K shall be incorporated by reference into any Registration Statement filed by the Registrant that by its terms automatically incorporates the Registrant's filings and submissions with the SEC under Sections 13(a), 13(c) or 15(d) of the Securities Exchange Act of 1934.

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

AMDOCS LIMITED
CONSOLIDATED BALANCE SHEETS
(dollar and share amounts in thousands, except per share data)

| | As of | |
|--|----------------------------------|-----------------------|
| | March 31, 2026 (Unaudited) | September 30, 2025 |
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 214,495 | \$ 324,999 |
| Accounts receivable, net | 938,182 | 935,751 |
| Prepaid expenses and other current assets | 364,347 | 331,387 |
| Total current assets | 1,517,024 | 1,592,137 |
| Property and equipment, net | 738,836 | 768,557 |
| Lease assets | 179,580 | 182,088 |
| Goodwill | 2,985,826 | 2,890,680 |
| Intangible assets, net | 258,069 | 156,282 |
| Other noncurrent assets | 684,535 | 660,086 |
| Total assets | \$ 6,363,870 | \$ 6,249,830 |
| LIABILITIES AND EQUITY | | |
| Current liabilities: | | |
| Accounts payable | \$ 344,106 | \$ 371,173 |
| Accrued expenses and other current liabilities | 639,168 | 622,748 |
| Accrued personnel costs | 125,568 | 207,285 |
| Short-term financing arrangements | 250,000 | — |
| Lease liabilities | 36,017 | 38,725 |
| Deferred revenue | 152,434 | 118,861 |
| Total current liabilities | 1,547,293 | 1,358,792 |
| Deferred income taxes and taxes payable | 228,704 | 218,766 |
| Lease liabilities | 134,567 | 140,776 |
| Long-term debt, net of unamortized debt issuance costs | 647,211 | 646,901 |
| Other noncurrent liabilities | 382,672 | 413,915 |
| Total liabilities | 2,940,447 | 2,779,150 |
| Equity: | | |
| Amdocs Limited Shareholders' equity: | | |
| Preferred Shares — Authorized 25,000 shares; £0.01 par value; 0 shares issued and outstanding | — | — |
| Ordinary Shares — Authorized 700,000 shares; £0.01 par value; 291,821 and 290,351 issued and 106,164 and 108,448 outstanding, respectively | 4,642 | 4,622 |
| Additional paid-in capital | 4,654,902 | 4,573,016 |
| Treasury stock, at cost 185,657 and 181,903 ordinary shares, respectively | (8,620,287) | (8,335,774) |
| Accumulated other comprehensive (loss) income | (178) | 22,635 |
| Retained earnings | 7,343,213 | 7,164,954 |
| Total Amdocs Limited Shareholders' equity | 3,382,292 | 3,429,453 |
| Noncontrolling interests | 41,131 | 41,227 |
| Total equity | 3,423,423 | 3,470,680 |
| Total liabilities and equity | \$ 6,363,870 | \$ 6,249,830 |

The accompanying notes are an integral part of these consolidated financial statements.

AMDOCS LIMITED
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(dollar and share amounts in thousands, except per share data)

| | Three months ended March 31, | | Six months ended March 31, | |
|---|---------------------------------|-------------------|-------------------------------|-------------------|
| | 2026 | 2025 | 2026 | 2025 |
| Revenue | \$ 1,171,979 | \$ 1,128,203 | \$ 2,327,918 | \$ 2,238,258 |
| Operating expenses: | | | | |
| Cost of revenue | 716,733 | 698,049 | 1,444,456 | 1,380,308 |
| Research and development | 87,001 | 81,796 | 168,979 | 166,129 |
| Selling, general and administrative | 153,677 | 134,625 | 267,398 | 256,712 |
| Amortization of purchased intangible assets and other | 21,308 | 15,998 | 35,842 | 31,757 |
| Restructuring charges | 10,405 | — | 21,706 | 6,783 |
| | <u>989,124</u> | <u>930,468</u> | <u>1,938,381</u> | <u>1,841,689</u> |
| Operating income | 182,855 | 197,735 | 389,537 | 396,569 |
| Interest and other expense, net | (5,963) | (8,465) | (17,228) | (14,874) |
| Income before income taxes | 176,892 | 189,270 | 372,309 | 381,695 |
| Income taxes | 38,120 | 25,269 | 75,083 | 65,842 |
| Net income | <u>\$ 138,772</u> | <u>\$ 164,001</u> | <u>\$ 297,226</u> | <u>\$ 315,853</u> |
| Net income attributable to noncontrolling interests | 957 | 758 | 1,845 | 1,477 |
| Net income attributable to Amdocs Limited | <u>\$ 137,815</u> | <u>\$ 163,243</u> | <u>\$ 295,381</u> | <u>\$ 314,376</u> |
| Basic earnings per share attributable to Amdocs Limited | \$ 1.29 | \$ 1.46 | \$ 2.75 | \$ 2.80 |
| Diluted earnings per share attributable to Amdocs Limited | \$ 1.28 | \$ 1.45 | \$ 2.74 | \$ 2.78 |
| Cash dividends declared per ordinary share | <u>\$ 0.569</u> | <u>\$ 0.527</u> | <u>\$ 1.096</u> | <u>\$ 1.006</u> |

The accompanying notes are an integral part of these consolidated financial statements.

AMDOCS LIMITED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
(dollar amounts in thousands)

| | Three months ended March 31, | | Six months ended March 31, | |
|---|---------------------------------|------------|-------------------------------|------------|
| | 2026 | 2025 | 2026 | 2025 |
| Net income | \$ 138,772 | \$ 164,001 | \$ 297,226 | \$ 315,853 |
| Other comprehensive (loss) income, net of tax: | | | | |
| Net change in fair value of cash flow hedges(1) | (19,246) | (5,590) | (22,813) | (3,396) |
| Net change in fair value of available-for-sale securities(2) | — | 1,853 | — | 2,810 |
| Other comprehensive loss, net of tax | (19,246) | (3,737) | (22,813) | (586) |
| Comprehensive income | \$ 119,526 | \$ 160,264 | \$ 274,413 | \$ 315,267 |
| Comprehensive income attributable to noncontrolling interests | 957 | 758 | 1,845 | 1,477 |
| Comprehensive income attributable to Amdocs Limited | \$ 118,569 | \$ 159,506 | \$ 272,568 | \$ 313,790 |

- (1) Net of tax of \$696 and \$710 for the three months ended March 31, 2026 and 2025, respectively, and of \$800 and \$191 for the six months ended March 31, 2026 and 2025, respectively.
- (2) No tax impact for the three and six months ended March 31, 2026 and 2025.

The accompanying notes are an integral part of these consolidated financial statements.

AMDOCS LIMITED
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
(dollar and share amounts in thousands, except per share data)

| | Ordinary Shares | | Additional Paid-in Capital | Treasury Stock | Accumulated Other Comprehensive Loss (1) | Retained Earnings | Total Amdocs Limited Shareholders' Equity | Non-controlling Interests | Total Equity |
|--|-----------------|-----------------|----------------------------|-----------------------|--|---------------------|---|---------------------------|---------------------|
| | Shares | Amount | | | | | | | |
| Balance as of December 31, 2025 | 107,571 | \$ 4,635 | \$ 4,615,417 | \$ (8,481,942) | \$ 19,068 | \$ 7,265,827 | \$ 3,423,005 | \$ 42,115 | \$ 3,465,120 |
| Comprehensive income: | | | | | | | | | |
| Net income | — | — | — | — | — | 137,815 | 137,815 | 957 | 138,772 |
| Other comprehensive loss | — | — | — | — | (19,246) | — | (19,246) | — | (19,246) |
| Comprehensive income | — | — | — | — | — | — | 118,569 | 957 | 119,526 |
| Employee stock options exercised | 23 | — | 1,486 | — | — | — | 1,486 | — | 1,486 |
| Repurchase of shares | (1,922) | — | — | (138,345) | — | — | (138,345) | — | (138,345) |
| Cash dividends declared (\$0.569 per ordinary share) | — | — | — | — | — | (60,429) | (60,429) | — | (60,429) |
| Issuance of restricted stock, net of forfeitures | 492 | 7 | — | — | — | — | 7 | — | 7 |
| Employee share purchase plan | — | — | — | — | — | — | — | — | — |
| Equity-based compensation expense related to employees | — | — | 37,999 | — | — | — | 37,999 | — | 37,999 |
| Distribution to noncontrolling interests | — | — | — | — | — | — | — | (1,941) | (1,941) |
| Balance as of March 31, 2026 | <u>106,164</u> | <u>\$ 4,642</u> | <u>\$ 4,654,902</u> | <u>\$ (8,620,287)</u> | <u>\$ (178)</u> | <u>\$ 7,343,213</u> | <u>\$ 3,382,292</u> | <u>\$ 41,131</u> | <u>\$ 3,423,423</u> |
| | | | | | | | | | |
| | Ordinary Shares | | Additional Paid-in Capital | Treasury Stock | Accumulated Other Comprehensive (Loss) (1) | Retained Earnings | Total Amdocs Limited Shareholders' Equity | Non-controlling Interests | Total Equity |
| | Shares | Amount | | | | | | | |
| Balance as of December 31, 2024 | 112,163 | \$ 4,610 | \$ 4,464,706 | \$ (7,928,917) | \$ (1,259) | \$ 6,925,123 | \$ 3,464,263 | \$ 41,597 | \$ 3,505,860 |
| Comprehensive income: | | | | | | | | | |
| Net income | — | — | — | — | — | 163,243 | 163,243 | 758 | 164,001 |
| Other comprehensive loss | — | — | — | — | (3,737) | — | (3,737) | — | (3,737) |
| Comprehensive income | — | — | — | — | — | — | 159,506 | 758 | 160,264 |
| Employee stock options exercised | 80 | 1 | 5,180 | — | — | — | 5,181 | — | 5,181 |
| Repurchase of shares | (1,537) | — | — | (135,237) | — | — | (135,237) | — | (135,237) |
| Cash dividends declared (\$0.527 per ordinary share) | — | — | — | — | — | (58,615) | (58,615) | — | (58,615) |
| Issuance of restricted stock, net of forfeitures | 513 | 6 | — | — | — | — | 6 | — | 6 |
| Equity-based compensation expense related to employees | — | — | 25,653 | — | — | — | 25,653 | — | 25,653 |
| Distribution to noncontrolling interests | — | — | — | — | — | — | — | (886) | (886) |
| Balance as of March 31, 2025 | <u>111,219</u> | <u>\$ 4,617</u> | <u>\$ 4,495,539</u> | <u>\$ (8,064,154)</u> | <u>\$ (4,996)</u> | <u>\$ 7,029,751</u> | <u>\$ 3,460,757</u> | <u>\$ 41,469</u> | <u>\$ 3,502,226</u> |

(1) As of March 31, 2026 and 2025, accumulated other comprehensive (loss) income is comprised of unrealized gain (loss) on derivatives, net of tax, of \$1,449 and \$(359) unrealized loss on short-term interest-bearing investments, net of tax, of \$(-) and \$(2,428), and unrealized loss on defined benefit plan, net of tax, of \$(1,627) and \$(2,209), respectively.

The accompanying notes are an integral part of these consolidated financial statements.

AMDOCS LIMITED
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
(dollar and share amounts in thousands, except per share data)

| | Ordinary Shares | | Additional Paid-in Capital | Treasury Stock | Accumulated Other Comprehensive Loss (1) | Retained Earnings | Total Amdocs Limited Shareholders' Equity | Non-controlling Interests | Total Equity |
|--|-----------------|-----------------|----------------------------|-----------------------|--|---------------------|---|---------------------------|---------------------|
| | Shares | Amount | | | | | | | |
| Balance as of September 30, 2025 | 108,448 | \$ 4,622 | \$ 4,573,016 | \$ (8,335,774) | \$ 22,635 | \$ 7,164,954 | \$ 3,429,453 | \$ 41,227 | \$ 3,470,680 |
| Comprehensive income: | | | | | | | | | |
| Net income | — | — | — | — | — | 295,381 | 295,381 | 1,845 | 297,226 |
| Other comprehensive loss | — | — | — | — | (22,813) | — | (22,813) | — | (22,813) |
| Comprehensive income | — | — | — | — | — | — | 272,568 | 1,845 | 274,413 |
| Employee stock options exercised | 52 | — | 3,177 | — | — | — | 3,177 | — | 3,177 |
| Repurchase of shares | (3,754) | — | — | (284,513) | — | — | (284,513) | — | (284,513) |
| Cash dividends declared (\$1.096 per ordinary share) | — | — | — | — | — | (117,122) | (117,122) | — | (117,122) |
| Issuance of restricted stock, net of forfeitures | 1,162 | 16 | — | — | — | — | 16 | — | 16 |
| Employee share purchase plan | 256 | 4 | 16,620 | — | — | — | 16,624 | — | 16,624 |
| Equity-based compensation expense related to employees | — | — | 62,089 | — | — | — | 62,089 | — | 62,089 |
| Distribution to noncontrolling interests | — | — | — | — | — | — | — | (1,941) | (1,941) |
| Balance as of March 31, 2026 | <u>106,164</u> | <u>\$ 4,642</u> | <u>\$ 4,654,902</u> | <u>\$ (8,620,287)</u> | <u>\$ (178)</u> | <u>\$ 7,343,213</u> | <u>\$ 3,382,292</u> | <u>\$ 41,131</u> | <u>\$ 3,423,423</u> |

| | Ordinary Shares | | Additional Paid-in Capital | Treasury Stock | Accumulated Other Comprehensive (Loss) (1) | Retained Earnings | Total Amdocs Limited Shareholders' Equity | Non-controlling Interests | Total Equity |
|--|-----------------|-----------------|----------------------------|-----------------------|--|---------------------|---|---------------------------|---------------------|
| | Shares | Amount | | | | | | | |
| Balance as of September 30, 2024 | 112,891 | \$ 4,598 | \$ 4,413,503 | \$ (7,784,434) | \$ (4,410) | \$ 6,827,719 | \$ 3,456,976 | \$ 42,201 | \$ 3,499,177 |
| Comprehensive income: | | | | | | | | | |
| Net income | — | — | — | — | — | 314,376 | 314,376 | 1,477 | 315,853 |
| Other comprehensive loss | — | — | — | — | (586) | — | (586) | — | (586) |
| Comprehensive income | — | — | — | — | — | — | 313,790 | 1,477 | 315,267 |
| Employee stock options exercised | 213 | 3 | 13,347 | — | — | — | 13,350 | — | 13,350 |
| Repurchase of shares | (3,198) | — | — | (279,720) | — | — | (279,720) | — | (279,720) |
| Cash dividends declared (\$1.006 per ordinary share) | — | — | — | — | — | (112,344) | (112,344) | — | (112,344) |
| Issuance of restricted stock, net of forfeitures | 1,062 | 13 | — | — | — | — | 13 | — | 13 |
| Employee share purchase plan | 251 | 3 | 16,516 | — | — | — | 16,519 | — | 16,519 |
| Equity-based compensation expense related to employees | — | — | 52,173 | — | — | — | 52,173 | — | 52,173 |
| Distribution to noncontrolling interests | — | — | — | — | — | — | — | (2,209) | (2,209) |
| Balance as of March 31, 2025 | <u>111,219</u> | <u>\$ 4,617</u> | <u>\$ 4,495,539</u> | <u>\$ (8,064,154)</u> | <u>\$ (4,996)</u> | <u>\$ 7,029,751</u> | <u>\$ 3,460,757</u> | <u>\$ 41,469</u> | <u>\$ 3,502,226</u> |

The accompanying notes are an integral part of these consolidated financial statements.

AMDOCS LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(dollar amounts in thousands)

| | Six months ended March 31, | |
|---|-------------------------------|---------------------|
| | 2026 | 2025 |
| Cash Flow from Operating Activities: | | |
| Net income | \$ 297,226 | \$ 315,853 |
| Reconciliation of net income to net cash provided by operating activities: | | |
| Depreciation, amortization and impairment | 103,747 | 94,460 |
| Amortization of debt issuance cost | 310 | 300 |
| Equity-based compensation expense | 62,089 | 52,173 |
| Deferred income taxes | 24,148 | 2,296 |
| Loss from short-term interest-bearing investments | — | 1,739 |
| Net changes in operating assets and liabilities, net of amounts acquired: | | |
| Accounts receivable, net | (46,640) | 33,174 |
| Prepaid expenses and other current assets | (23,114) | (32,526) |
| Other noncurrent assets | 18,492 | 5,141 |
| Lease assets and liabilities, net | (6,408) | (1,194) |
| Accounts payable, accrued expenses and accrued personnel | (90,120) | (126,700) |
| Deferred revenue | 23,505 | 27,846 |
| Income taxes payable, net | (5,003) | (11,082) |
| Other noncurrent liabilities | (36,466) | (83,467) |
| Net cash provided by operating activities | <u>\$ 321,766</u> | <u>\$ 278,013</u> |
| Cash Flow from Investing Activities: | | |
| Purchase of property and equipment, net (a) | (53,476) | (43,319) |
| Proceeds from sale of short-term interest-bearing investments | — | 92,955 |
| Net cash paid for business and intangible assets acquisitions | (217,663) | (57,169) |
| Net cash from equity investments and other | 11,848 | 16,741 |
| Net cash (used) provided by investing activities | <u>\$ (259,291)</u> | <u>\$ 9,208</u> |
| Cash Flow from Financing Activities: | | |
| Repurchase of shares | (284,513) | (279,720) |
| Proceeds from employee stock option exercises | 3,193 | 11,422 |
| Payments of dividends | (113,849) | (107,810) |
| Distribution to noncontrolling interests | (1,941) | (2,209) |
| Borrowings under financing arrangements | 250,000 | — |
| Payment of contingent consideration and deferred payment of business acquisitions | (25,869) | (7,599) |
| Net cash used in financing activities | <u>\$ (172,979)</u> | <u>\$ (385,916)</u> |
| Net decrease in cash and cash equivalents | (110,504) | (98,695) |
| Cash and cash equivalents at beginning of period | 324,999 | 346,085 |
| Cash and cash equivalents at end of period | <u>\$ 214,495</u> | <u>\$ 247,390</u> |
| Supplementary Cash Flow Information | | |
| Cash paid for: | | |
| Income taxes, net of refunds (b) | \$ 59,475 | \$ 79,009 |
| Interest | 24,287 | 20,442 |

(a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment for the six months ended March 31, 2026 and 2025.

(b) For Further details, see also Note 10.

The accompanying notes are an integral part of these consolidated financial statements.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

1. Nature of Entity and Basis of Presentation

Amdocs Limited (the “Company”) is a leading provider of software and services to communications and media service providers of all sizes throughout the world. The Company and its consolidated subsidiaries operate in one segment and design, develop, market, support, implement and operate its open and modular cloud offering. The Company’s comprehensive portfolio of software products and services is designed to leverage artificial intelligence, driving digital transformation, accelerate cloud adoption, and enable intelligent network automation.

The Company is a Guernsey limited company, which directly or indirectly holds numerous subsidiaries around the world, the vast majority of which are wholly-owned. The majority of the Company’s customers are in North America, Europe, Asia-Pacific and the Latin America region. The Company maintains strategic development centers in Israel, Cyprus and India. The Company also has regional development centers in Brazil, Canada, Mexico, the Philippines, the United Kingdom and the United States.

The unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP and are denominated in U.S. dollars.

In the opinion of the Company’s management, all adjustments considered necessary for a fair presentation of the unaudited interim consolidated financial statements have been included herein and are of a normal recurring nature. The preparation of financial statements during interim periods requires management to make numerous estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses. Estimates and assumptions are reviewed periodically and the effect of revisions is reflected in the results of operations for the interim periods in which changes are determined to be necessary.

The results of operations for the interim periods presented herein are not necessarily indicative of the results to be expected for the full fiscal year. These statements do not include all information and footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with GAAP. These statements should be read in conjunction with the Company’s consolidated financial statements for the fiscal year ended September 30, 2025, set forth in the Company’s Annual Report on Form 20-F filed on December 15, 2025 with the U.S. Securities and Exchange Commission, or the SEC. There have been no material changes to the Company’s significant accounting policies from its Annual Report on Form 20-F for the fiscal year ended September 30, 2025.

Reclassification

From time to time, certain immaterial amounts in prior year financial statements may be reclassified to conform to the current year presentation.

2. Recent Accounting Standards

In December 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2025-11, *“Interim Reporting (Topic 270)”*, Narrow-Scope Improvements, which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The ASU provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. This ASU will be effective beginning with the Company’s interim fiscal year 2029, on a retrospective or prospective basis, with early adoption permitted. The Company is currently evaluating the impact of the adoption on its consolidated financial statements.

In November 2025, the FASB issued ASU No. 2025-09, *“Derivatives and Hedging (Topic 815)”*, which amends certain aspects of the hedge accounting. This ASU will be effective beginning with the Company’s interim fiscal year 2028, on a prospective basis, with early adoption permitted. The Company is currently evaluating the impact of the adoption on its consolidated financial statements.

In September 2025, the FASB issued ASU No. 2025-06, *“Intangibles - Goodwill and Other - Internal-Use Software”*, which will update the requirements around the capitalization and disclosure of internal-use software. This ASU will be effective beginning with the Company’s interim fiscal year 2029, with early adoption permitted and to be applied either prospectively, retroactively or a modified transition approach. The Company is currently evaluating the impact of the adoption on its consolidated financial statements.

In July 2025, the FASB issued ASU 2025-05, *“Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets.”* This ASU allows entities to apply a practical expedient when estimating expected credit losses for current accounts receivable and current contract assets. This ASU will be effective beginning with the Company’s interim fiscal year 2027 with early adoption permitted, and should be applied prospectively. The Company is currently evaluating the impact of the adoption on its consolidated financial statements.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures", to disclose in the notes of the financial statements additional information about specific expense categories. This ASU will be effective for the Company's annual report for fiscal year 2028 and for interim period reporting beginning in fiscal year 2029, with early adoption permitted and should be applied either prospectively or retroactively. The Company is currently evaluating the impact of the adoption on its consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures", which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. This ASU will be effective for the Company's annual report for fiscal year 2026 and allows adoption on a prospective basis, with a retrospective option. This ASU will only have an impact on the Company's income tax disclosures.

3. Acquisitions

During the six months ended March 31, 2026, the Company completed two business acquisitions for an aggregate net consideration of approximately \$217,000 in cash. The majority of this amount was paid for the acquisition of Matrixx Software, a privately owned company specializing in Charging & Rating solutions for global communication service providers. These acquisitions, individually and in the aggregate, were not material in the results of the period presented. In allocating the total consideration based on the preliminary estimated fair values for Matrixx Software, the Company recorded \$79,441 of goodwill, \$80,009 of customer relationships to be amortized over approximately six years, \$24,696 of core technology to be amortized over approximately seven years, and \$1,276 of trademark to be amortized over approximately one year.

During the six months ended March 31, 2025, the Company completed three business acquisitions for an aggregate net consideration of approximately \$59,000 in cash, and a potential for additional consideration which may be paid later based on achievement of certain performance metrics. The majority of this amount was paid for the acquisition of Profitit, a data science and engineering company. These acquisitions, individually and in the aggregate, were not material in the results of the period presented. In allocating the total consideration based on the preliminary estimated fair values for Profitit, the Company recorded \$29,418 of goodwill, and \$18,439 of customer relationships to be amortized over approximately five years.

4. Revenue

Contract Balances

The following table provides information about accounts receivable, both billed and unbilled and deferred revenue:

| | As of | |
|--|-------------------|-----------------------|
| | March 31, 2026 | September 30, 2025 |
| Accounts receivable - billed (net of allowance for credit losses of \$28,393 and \$26,169 as of March 31, 2026 and September 30, 2025, respectively) | \$ 653,444 | \$ 589,781 |
| Accounts receivable – unbilled (current) | 284,738 | 345,970 |
| Accounts receivable – unbilled (non-current) | 166,176 | 104,200 |
| Total Accounts receivable - unbilled | 450,914 | 450,170 |
| Deferred revenue (current) | (152,434) | (118,861) |
| Deferred revenue (non-current) | (10,597) | (9,889) |
| Total Deferred revenue | \$ (163,031) | \$ (128,750) |

Revenue recognized during the three and six months ended March 31, 2026, which was included in deferred revenue (current) as of September 30, 2025 was \$14,867 and \$94,497. Revenue recognized during the three and six months ended March 31, 2025, which was included in deferred revenue (current) as of September 30, 2024 was \$15,709 and \$84,753, respectively.

As of March 31, 2026, the aggregate amount of the transaction price allocated to remaining performance obligations that are unsatisfied or partially unsatisfied was approximately \$6.6 billion. Remaining performance obligations include the remaining non-cancelable, committed and fixed portion of these contracts for their entire duration and therefore it is not comparable to what the Company considers to be the next 12 months backlog. Given the profile of contract terms, the majority of this amount is expected to be recognized as revenue over the next two years. A portion of the Company's revenue relates to projects recognized over time based on a percentage that incurred labor effort to date bears to total projected labor effort. These projects may be executed over periods longer than one year, in which the timing of recognition is subject to a certain level of uncertainty.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

Disaggregation of Revenue

The Company considers information that is regularly reviewed by its chief operating decision maker in evaluating financial performance to disaggregate revenue.

The following tables provide details of revenue by nature of activities and by geography:

Revenue by nature of activities

| | Three months ended March 31, | | Six months ended March 31, | |
|-------------------------------|---------------------------------|---------------------|-------------------------------|---------------------|
| | 2026 | 2025 | 2026 | 2025 |
| Managed services arrangements | \$ 758,704 | \$ 747,108 | \$ 1,504,602 | \$ 1,475,963 |
| Others | 413,275 | 381,095 | 823,316 | 762,295 |
| Total | \$ 1,171,979 | \$ 1,128,203 | \$ 2,327,918 | \$ 2,238,258 |

Geographic Information

| | Three months ended March 31, | | Six months ended March 31, | |
|--------------------------------------|---------------------------------|---------------------|-------------------------------|---------------------|
| | 2026 | 2025 | 2026 | 2025 |
| North America (mainly United States) | \$ 754,305 | \$ 738,335 | \$ 1,519,006 | \$ 1,475,731 |
| Europe | 191,832 | 180,676 | 373,561 | 335,908 |
| Rest of the world | 225,842 | 209,192 | 435,351 | 426,619 |
| Total | \$ 1,171,979 | \$ 1,128,203 | \$ 2,327,918 | \$ 2,238,258 |

5. Fair Value Measurement

The Company accounts for certain assets and liabilities at fair value. Fair value is the price that would be received from selling an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety.

The three levels of inputs that may be used to measure fair value are as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities;

Level 2: Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets), or other inputs that are observable (model-derived valuations in which significant inputs are observable) or can be derived principally from, or corroborated by, observable market data; and

Level 3: Unobservable inputs that are supported by little or no market activity that is significant to the fair value of the assets or liabilities.

The following tables present the Company's assets and liabilities measured at fair value on a recurring basis as of March 31, 2026 and September 30, 2025:

| | As of March 31, 2026 | | | |
|--|----------------------|-----------------|-----------------|------------------|
| | Level 1 | Level 2 | Level 3 | Total |
| Available-for-sale securities - money market funds | \$ 5,659 | \$ — | \$ — | \$ 5,659 |
| Equity Investments | — | — | 31,408 | 31,408 |
| Derivative financial instruments, net | — | 2,344 | — | 2,344 |
| Acquisition-related liabilities | — | — | (28,341) | (28,341) |
| Total | \$ 5,659 | \$ 2,344 | \$ 3,067 | \$ 11,070 |

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

| | As of September 30, 2025 | | | Total |
|--|--------------------------|------------------|--------------------|-------------------|
| | Level 1 | Level 2 | Level 3 | |
| Available-for-sale securities - money market funds | \$ 118,163 | \$ — | \$ — | \$ 118,163 |
| Equity Investments | — | — | 32,540 | 32,540 |
| Derivative financial instruments, net | — | 29,780 | — | 29,780 |
| Acquisition-related liabilities | — | — | (49,649) | (49,649) |
| Total | \$ 118,163 | \$ 29,780 | \$ (17,109) | \$ 130,834 |

The Company's derivative instruments are classified as Level 2 as they represent foreign currency forward and option contracts valued primarily based on observable inputs including forward rates and yield curves. The Company did not have any transfers between Level 1 and Level 2 fair value measurements during the three and six months ended March 31, 2026. Level 3 liabilities relate to certain acquisition-related liabilities, which were generally valued using a Monte-Carlo simulation model and based on estimates of potential pay-out scenarios, valued every quarter. These liabilities were included in both accrued expenses and other current liabilities and other noncurrent liabilities as of March 31, 2026 and September 30, 2025. The decrease in Level 3 liabilities was primarily attributable to payments of certain acquisition-related liabilities, changes in the fair value recorded in the consolidated statement of income during the three and six months ended March 31, 2026, which were partially offset by new acquisition-related liabilities recorded against goodwill in connection with recent acquisition. The slight decrease in Level 3 assets is primarily due to sales of equity investments, partially offset by net positive changes in fair value recorded in the consolidated statement of income for the three and six months ended March 31, 2026.

Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other current liabilities, accrued personnel costs, short-term financing arrangements, approximate their fair value because of the relatively short maturity of these items, for the fair value of the Senior Notes, see Note 13.

6. Available-For-Sale Securities

Available-for-sale securities consist of the following interest-bearing investments:

| | As of March 31, 2026 | | | Fair Value |
|-----------------------|----------------------|------------------------|-------------------------|------------|
| | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | |
| Money market funds(1) | \$ 5,659 | \$ — | \$ — | \$ 5,659 |

| | As of September 30, 2025 | | | Fair Value |
|------------------------|--------------------------|------------------------|-------------------------|------------|
| | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | |
| Money market funds (1) | \$ 118,163 | \$ — | \$ — | \$ 118,163 |

(1) As of March 31, 2026 and September 30, 2025, all the securities were classified as cash and cash equivalents.

The Company did not recognize any credit losses based on its assessment during the three and six months ended March 31, 2026 and 2025. Realized gains and losses on short-term interest-bearing investments are included in earnings and are determined based on specific identification method.

As of March 31, 2026, the Company's available-for-sale securities had the following maturity dates:

| | Market Value |
|---------------------|--------------|
| Due within one year | \$ 5,659 |

7. Derivative Financial Instruments

The Company's risk management strategy includes the use of derivative financial instruments to reduce the volatility of earnings and cash flows associated with changes in foreign currency exchange rates. The Company does not enter into derivative transactions for trading purposes.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

The Company's derivatives expose it to credit risks from possible non-performance by counterparties. The Company utilizes standard counterparty master netting agreements that net certain foreign currency transactions in the event of the insolvency of one of the parties to the transaction. These master netting arrangements permit the Company to net amounts due from the Company to a counterparty with amounts due to the Company from the same counterparty. Although all of the Company's recognized derivative assets and liabilities are subject to enforceable master netting arrangements, the Company has elected to present these assets and liabilities on a gross basis. Taking into account the Company's right to net certain gains with losses, the maximum amount of loss due to credit risk that the Company would incur if all counterparties to the derivative financial instruments failed completely to perform, according to the terms of the contracts, based on the gross fair value of the Company's derivative contracts that are favorable to the Company, was approximately \$22,643 as of March 31, 2026. The Company has limited its credit risk by entering into derivative transactions exclusively with investment-grade rated financial institutions and monitors the creditworthiness of these financial institutions on an ongoing basis.

The Company classifies cash flows from its derivative transactions as cash flows from operating activities in the consolidated statements of cash flows.

The table below presents the total volume or notional amounts of the Company's derivative instruments as of March 31, 2026. Notional values are in U.S. dollars and are translated and calculated based on forward rates as of March 31, 2026 for forward contracts.

| | Notional Value* |
|----------------------------|------------------------|
| Foreign exchange contracts | \$ 1,677,031 |

* Gross notional amounts do not quantify risk or represent assets or liabilities of the Company but are used in the calculation of settlements under the contracts.

The Company records all derivative instruments on the consolidated balance sheets at fair value. For further information, please see Note 5 to the consolidated financial statements. The fair value of the open foreign exchange contracts recorded as an asset or a liability by the Company on its consolidated balance sheets as of March 31, 2026 and September 30, 2025, is as follows:

| | As of | |
|---|---------------------------|-------------------------------|
| | March 31, 2026 | September 30, 2025 |
| <i>Derivatives designated as hedging instruments</i> | | |
| Prepaid expenses and other current assets | \$ 21,551 | \$ 31,524 |
| Accrued expenses and other current liabilities | (15,200) | (6,235) |
| Other noncurrent liabilities | (4,653) | — |
| | 1,698 | 25,289 |
| <i>Derivatives not designated as hedging instruments</i> | | |
| Prepaid expenses and other current assets | \$ 14,044 | \$ 11,898 |
| Accrued expenses and other current liabilities | (13,398) | (7,407) |
| | 646 | 4,491 |
| Net fair value | \$ 2,344 | \$ 29,780 |

Cash Flow Hedges

In order to reduce the impact of changes in foreign currency exchange rates on its results, the Company enters into foreign currency exchange forward and option contracts to purchase and sell foreign currencies to hedge a significant portion of its foreign currency net exposure resulting from revenue and expense transactions denominated in currencies other than the U.S. dollar. The Company designates these contracts for accounting purposes as cash flow hedges. The Company hedges its exposure to the variability in future cash flows for a maximum period of approximately three years.

The effective portion of the gain or loss on the derivative instruments is initially recorded as a component of other comprehensive loss, net, a separate component of equity, and subsequently reclassified into earnings in the same line item as the related forecasted transaction and in the same period or periods during which the hedged exposure affects earnings. The cash flow hedges are evaluated for effectiveness quarterly. As the critical terms of the forward contract or option and the hedged transaction are matched at inception, the hedge effectiveness is assessed generally based on changes in the fair value for cash flow hedges, as compared to the changes in the fair value of the cash flows associated with the underlying hedged transactions. Hedge ineffectiveness, if any, is recognized immediately in interest and other expense, net.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

The effect of the Company's cash flow hedging instruments in the consolidated statements of income for the three and six months ended March 31, 2026 and 2025, respectively, which partially offsets the foreign currency impact from the underlying exposures, is summarized as follows:

| Line item in consolidated statements of income: | Gains (Losses) Reclassified from | | | |
|---|---|---------------|------------------------------|-----------------|
| | Accumulated Other Comprehensive (Loss) Income (Effective Portion) | | Three months ended March 31, | |
| | 2026 | 2025 | 2026 | 2025 |
| Revenue | (465) | \$ 71 | (1,024) | \$ 71 |
| Cost of revenue | 4,530 | (222) | 10,070 | (1,052) |
| Research and development | 2,198 | 89 | 4,313 | (48) |
| Selling, general and administrative | 2,847 | 191 | 5,376 | 126 |
| Total | <u>\$ 9,110</u> | <u>\$ 129</u> | <u>\$ 18,735</u> | <u>\$ (903)</u> |

The activity related to the changes in net unrealized gains (losses) on cash flow hedges recorded in accumulated other comprehensive (loss) income, net of tax, is as follows:

| | Six months ended March 31, | | | |
|--|----------------------------|--------------|-----------|--------------|
| | 2026 | 2025 | 2026 | 2025 |
| Net unrealized gains (losses) on cash flow hedges, net of tax, beginning of period | \$ | 24,262 | \$ | 3,037 |
| Changes in fair value of cash flow hedges, net of tax | | (5,782) | | (4,383) |
| Reclassification of net (gains) losses into earnings, net of tax | | (17,031) | | 987 |
| Net unrealized gains (losses) on cash flow hedges, net of tax, end of period | <u>\$</u> | <u>1,449</u> | <u>\$</u> | <u>(359)</u> |

Net (losses) gains from cash flow hedges recognized in other comprehensive loss were \$(4,878) and \$(4,490), or \$(5,782) and \$(4,383) net of taxes, during the six months ended March 31, 2026 and 2025, respectively.

Of the net unrealized gains (losses) related to derivatives designated as cash flow hedges and recorded in accumulated other comprehensive (loss) income as of March 31, 2026, a net gains of \$5,013 will be reclassified into earnings within the next 12 months and will partially offset the foreign currency impact from the underlying exposures. The amount ultimately realized in earnings will likely differ due to future changes in foreign exchange rates.

The ineffective portion of the change in fair value of a cash flow hedge, including the time value portion excluded from effectiveness testing for the three and six months ended March 31, 2026 and 2025, was not material.

Other Risk Management Derivatives

The Company also enters into foreign currency exchange forward and option contracts that are not designated as hedging instruments under hedge accounting and are used to reduce the impact of foreign currency on certain balance sheet exposures and certain revenue and expense transactions.

These instruments are generally short-term in nature, with typical maturities of less than 12 months, and are subject to fluctuations in foreign exchange rates.

The effect of the Company's derivative instruments not designated as hedging instruments in the consolidated statements of income for the three and six months ended March 31, 2026 and 2025, respectively, which partially offsets the foreign currency impact from the underlying exposure, is summarized as follows:

| Line item in consolidated statements of income: | Gains (Losses) Recognized in Income | | | |
|---|-------------------------------------|-------------------|----------------------------|-----------------|
| | Three months ended March 31, | | Six months ended March 31, | |
| | 2026 | 2025 | 2026 | 2025 |
| Cost of revenue | \$ (1,759) | \$ (21) | \$ 300 | \$ (1,444) |
| Research and development | (97) | (158) | 561 | (192) |
| Selling, general and administrative | (203) | (97) | 547 | (358) |
| Interest and other expense, net | (416) | (8,043) | (1,256) | 7,258 |
| Income taxes | 1,509 | (496) | 1,646 | 361 |
| Total | <u>\$ (966)</u> | <u>\$ (8,815)</u> | <u>\$ 1,798</u> | <u>\$ 5,625</u> |

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

8. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

| | As of | |
|---|-------------------|-----------------------|
| | March 31, 2026 | September 30, 2025 |
| Ongoing accrued expenses | \$ 342,430 | \$ 332,321 |
| Project-related provisions | 17,200 | 26,143 |
| Dividends payable | 60,429 | 57,156 |
| Taxes payable (1) | 44,984 | 34,131 |
| Derivative instruments | 28,598 | 13,642 |
| Other | 145,527 | 159,355 |
| Accrued expenses and other current liabilities | \$ 639,168 | \$ 622,748 |

(1) For further details, please see Note 10 to the consolidated financial statements.

9. Restructuring charges

Further to the Company's restructuring activities in recent years, the Company has undertaken certain additional restructuring actions to focus on operational excellence, automation and the internal deployment of generative AI based tools across its operations. Total restructuring expenses recognized in fiscal years 2024 and 2025 were \$131,088 and \$80,539, respectively. During the three and six months ended March 31, 2026, the Company incurred restructuring charges of \$10,405 and \$21,706, respectively. The Company expects to pay the outstanding restructuring related liability during the coming several quarters and continues to evaluate further operational efficiencies.

The restructuring activities as of March 31, 2026 were as follows (*):

| | Workforce | Premises and other | Total |
|-----------------------------------|------------------|--------------------|------------------|
| Liability as of October 1, 2025 | \$ 70,274 | \$ 2,684 | \$ 72,958 |
| Restructuring charges | 4,733 | 6,568 | 11,301 |
| Payments | (44,030) | (38) | (44,068) |
| Non-Cash items | 644 | (4,390) | (3,746) |
| Liability as of December 31, 2025 | \$ 31,621 | \$ 4,824 | \$ 36,445 |
| Restructuring Charges | 7,934 | 2,471 | 10,405 |
| Payments | (14,480) | (976) | (15,456) |
| Non-Cash items | 8 | (2,541) | (2,533) |
| Liability as of March 31, 2026 | \$ 25,083 | \$ 3,778 | \$ 28,861 |

(*) The table above does not include amounts related to employees' benefit incurred in prior periods.

10. Income Taxes

The provision for income taxes for the following periods consisted of:

| | Three months ended March 31, | | Six months ended March 31, | |
|---------------------|------------------------------------|------------------|----------------------------------|------------------|
| | 2026 | 2025 | 2026 | 2025 |
| Current | \$ 29,124 | \$ 24,624 | \$ 50,935 | \$ 63,546 |
| Deferred | 8,996 | 645 | 24,148 | 2,296 |
| Income taxes | \$ 38,120 | \$ 25,269 | \$ 75,083 | \$ 65,842 |

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

The Company's effective income tax rate varied from the statutory Guernsey tax rate as follows for the following periods:

| | Three months ended March 31, | | Six months ended March 31, | | |
|-----------------------------|---------------------------------|-------|-------------------------------|-------|------|
| | 2026 | 2025 | 2026 | 2025 | 2025 |
| Statutory Guernsey tax rate | 0% | 0% | 0% | 0% | 0% |
| Foreign taxes (1) | 21.5 | 13.4 | 20.2 | 17.2 | |
| Effective income tax rate | 21.5% | 13.4% | 20.2% | 17.2% | |

As a Guernsey company subject to a corporate tax rate of zero percent, the Company's overall effective tax rate is attributable to foreign taxes. The change in rate is primarily driven by discrete items in the respective period presented as outlined below.

(1) Foreign taxes for the six months ended March 31, 2026:

In the six months ended March 31, 2026, the Company recorded a tax benefit of \$15,404 primarily related to release of gross unrecognized tax benefits due to a change in measurement of tax positions and expiration of the periods set forth in statutes of limitations in certain jurisdictions.

During the six months ended March 31, 2026, the Company also recognized a tax benefit of \$10,563 included in foreign taxes, primarily related to the amendment of certain tax returns.

(1) Foreign taxes for the six months ended March 31, 2025:

In the six months ended March 31, 2025, the Company recorded a tax benefit of \$16,010 related to the release of prior periods accrued withholding taxes on unremitted earnings accumulated in a certain jurisdiction. The release of the accrued withholding taxes followed the Company's funding decisions relating to investment allocation decision.

Foreign taxes in the six months ended March 31, 2025 also included a benefit of \$4,991 relating primarily to release of gross unrecognized tax benefits due to expiration of the periods set forth in statutes of limitations in certain jurisdictions, and settlements of tax audits.

As of March 31, 2026, deferred tax assets of \$66,634, derived primarily from tax credits, net capital and operating loss carry forwards related to some of the Company's subsidiaries, were offset by valuation allowances due to the uncertainty of realizing tax benefit for such credits and losses.

The total amount of gross unrecognized tax benefits, was \$174,906 as of March 31, 2026, all of which would affect the effective tax rate if realized. This amount includes an accrual of \$42,235 in income taxes payable for interest and penalties relating to unrecognized tax benefits.

The Company is currently under tax audit in several jurisdictions for the tax years 2007 and onwards. Timing of the resolution of audits is highly uncertain and therefore, as of March 31, 2026, the Company cannot estimate the change in unrecognized tax benefits resulting from these audits within the next 12 months.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

11. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:

| | Three months ended March 31, | | Six months ended March 31, | |
|---|---------------------------------|-------------------|-------------------------------|-------------------|
| | 2026 | 2025 | 2026 | 2025 |
| Numerator: | | | | |
| Net income attributable to Amdocs Limited | \$ 137,815 | \$ 163,243 | \$ 295,381 | \$ 314,376 |
| Net income and dividends attributable to participating restricted stock | (2,775) | (3,080) | (5,814) | (5,861) |
| Numerator for basic earnings per ordinary share | <u>\$ 135,040</u> | <u>\$ 160,163</u> | <u>\$ 289,567</u> | <u>\$ 308,515</u> |
| Undistributed income allocated to participating restricted stock | 1,548 | 1,967 | 3,494 | 3,754 |
| Undistributed income reallocated to participating restricted stock | (1,543) | (1,957) | (3,479) | (3,733) |
| Numerator for diluted earnings per ordinary share | <u>\$ 135,045</u> | <u>\$ 160,173</u> | <u>\$ 289,582</u> | <u>\$ 308,536</u> |
| Denominator: | | | | |
| Weighted average number of shares outstanding - basic | 107,095 | 111,961 | 107,541 | 112,357 |
| Weighted average number of participating restricted stock | (2,156) | (2,112) | (2,117) | (2,095) |
| Weighted average number of ordinary shares - basic | <u>104,939</u> | <u>109,849</u> | <u>105,424</u> | <u>110,262</u> |
| Effect of dilutive equity-based compensation awards | 377 | 553 | 456 | 624 |
| Weighted average number of ordinary shares - diluted | <u>105,316</u> | <u>110,402</u> | <u>105,880</u> | <u>110,886</u> |
| Basic earnings per ordinary share attributable to Amdocs Limited | <u>\$ 1.29</u> | <u>\$ 1.46</u> | <u>\$ 2.75</u> | <u>\$ 2.80</u> |
| Diluted earnings per ordinary share attributable to Amdocs Limited | <u>\$ 1.28</u> | <u>\$ 1.45</u> | <u>\$ 2.74</u> | <u>\$ 2.78</u> |

For the three and six months ended March 31, 2026, 244 and 175 shares, respectively, on a weighted average basis, were attributable to antidilutive outstanding equity-based compensation awards. For the three and six months ended March 31, 2025, 240 and 150, respectively, on a weighted average basis, were attributable to antidilutive outstanding stock options and restricted stock units. Shares attributable to antidilutive outstanding stock equity-based compensation awards were not included in the calculation of diluted earnings per share.

12. Repurchase of Shares

From time to time, the Company's Board of Directors can adopt share repurchase plans authorizing the repurchase of the Company's outstanding ordinary shares. On May 7, 2025, the Company's Board of Directors adopted a share repurchase plan for the repurchase of up to an additional \$1.0 billion of the Company's outstanding ordinary shares with no expiration date. The May 2025 plan permits the Company to purchase our ordinary shares in the open market or through privately negotiated transactions at times and prices that the Company considers appropriate. During the six months ended March 31, 2026, the Company repurchased 3,754 ordinary shares at an average price of \$75.78 per share (excluding broker and transaction fees). As of March 31, 2026, the Company had remaining authority to repurchase up to \$701,943 of its outstanding ordinary shares under the May 2025 plan.

13. Financing Arrangements

In December 2011, the Company entered into an unsecured \$500,000 five-year revolving credit facility with a syndicate of banks (the "Revolving Credit Facility"). In December 2014, December 2017, March 2021 and July 2024, the Revolving Credit Facility was amended and restated to, among other things, extend the maturity date of the facility to December 2019, December 2022 March 2026 and July 2029, respectively. In March 2026 the Revolving Credit Facility was amended to increase the amount from \$500,000 to an aggregate amount of \$800,000. As of March 31, 2026, the Company was in compliance with the financial covenants and had \$170,000 outstanding borrowing under the Revolving Credit Facility, as a result, \$630,000 remains available on the Revolving Credit Facility.

In March 2026, the Company established a commercial paper program, supported by the Revolving Credit Facility under which it may issue unsecured commercial paper up to a total of \$800,000 outstanding at any time, with maturities of up to 397 days from the date of issue. The net proceeds from the issuance of commercial paper are expected to be used for general corporate purposes. As of March 31, 2026, there was no outstanding borrowing amount under the commercial paper program.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

In June 2020, the Company issued an aggregate principal amount of \$650,000 in Senior Notes that will mature in June 2030 and bear interest at a fixed rate of 2.538 percent per annum (the "Senior Notes"). The interest is payable semi-annually in June and December of each year, commencing in December 2020. The Company incurred issuance costs of \$6,121 in relation with the Senior Notes, which are being amortized to interest expenses over the term of the Senior Notes using the effective interest rate. The Senior Notes are senior unsecured obligations of the Company and rank equally in right of payment with all existing and future senior indebtedness of the Company, including any indebtedness the Company may incur from time to time under the Revolving Credit Facility.

The total interest expense recognized in connection with the Senior Notes for the three and six months ended March 31, 2026 were \$4,211 and \$8,532, respectively, and \$4,207 and \$8,524 for three and six months ended March 31, 2025. The accrued interest on the Senior Notes is included in accrued expenses and other current liabilities and was \$4,795 as of March 31, 2026. As of March 31, 2026, the noncurrent outstanding principal portion was \$650,000.

The total estimated fair value of the Senior Notes as of March 31, 2026 was \$588,010. The fair value was determined based on observable data, such as quoted prices for similar liabilities in active markets of Senior Notes as of March 31, 2026 and is deemed a Level 2 liability within the fair value measurement framework.

As of March 31, 2026, the Company had additional uncommitted lines of credit available for general corporate and other specific purposes and had \$80,000 outstanding borrowing under the uncommitted lines of credit. As of March 31, 2026, the Company had outstanding letters of credit and bank guarantees from various banks totaling \$90,690, which were supported by a combination of the uncommitted lines of credit that we maintain with various banks.

14. Equity-based Compensation

Equity Incentive Plan

In January 1998, the Company adopted the 1998 Stock Option and Incentive Plan, or Equity Incentive Plan, which provides for the grant of restricted stock awards, restricted stock units and stock options and other equity-based awards to employees, officers, directors, and consultants. Since its adoption, the Equity Incentive Plan has been amended on several occasions to, among other things, increase the number of ordinary shares issuable under the Equity Incentive Plan. In February 2024, the maximum number of ordinary shares authorized to be granted under the Equity Incentive Plan was increased from 70,550 to 73,550. The amendment to the Equity Incentive Plan became effective upon the filing of a Form S-8 Registration Statement with the U.S. Securities and Exchange Commission in February 2024. Awards granted under the Equity Incentive Plan generally vest over a period of three to four years and are generally subject to service based conditions or a combination of service and performance-based conditions and stock options have a contractual term of primarily ten years. Also, in accordance with the Equity Incentive Plan, options were issued at or above the market price at the time of the grant.

During the six months ended March 31, 2026, the Company granted 1,107 restricted stock and 298 restricted stock units. The weighted average fair values associated with these grants were \$75.62 per restricted stock and \$76.02 per restricted stock unit.

Employee Share Purchase Plan

On November 8, 2022, the Company's Board of Directors adopted, subject to shareholder approval, the Amdocs Limited 2023 Employee Share Purchase Plan (the "ESPP"). The ESPP was subsequently approved by the Company's shareholders at the annual general meeting of shareholders in January 2023. The approved number of shares that may be issued under the ESPP will not exceed in the aggregate 2,400 ordinary shares. Under its terms, the ESPP became effective upon the filing of a Form S-8 Registration Statement with the U.S. Securities and Exchange Commission. On February 13, 2023, the Company filed a registration statement on Form S-8 registering the offer and sale of 2,400 ordinary shares issuable under the ESPP. As of March 31, 2026, 1,283 ordinary shares have been issued since the commencement of the ESPP.

In November 2025, the Company's Board of Directors approved, subject to approval by the Company's shareholders, an amendment to the ESPP. The ESPP was subsequently approved by the Company's shareholders at the annual general meeting of shareholders in January 2026. The amendment to the ESPP will increase the maximum number of the Company's ordinary shares that may be issued under the ESPP by 2,200 ordinary shares. Under its terms, the amendment to the ESPP became effective upon the filing of a Form S-8 Registration Statement with the U.S. Securities and Exchange Commission. On February 17, 2026, the Company filed a registration statement on Form S-8 registering the offer and sale of 2,200 ordinary shares issuable under the ESPP.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

Under the ESPP, eligible employees have the right to purchase ordinary shares at the end of each purchase period based on their accumulated payroll deductions during the purchase period of a specified percentage of eligible compensation up to 10% (subject to a limitation to accrue the right to purchase ordinary shares up to twenty-five thousand dollars in any calendar year). Each purchase period lasts six months in duration, with purchases occurring in December and June. The purchase price per ordinary share will equal the lesser of 85% of the fair market value of our ordinary shares at either the beginning of the purchase period or the end of the purchase period.

During the six months ended March 31, 2026, the Company issued 256 ordinary shares to employees under the ESPP at a weighted average price of \$64.94 per share.

Equity-based Compensation Expense

Equity-based payments to employees, including grants of employee stock options, restricted stock, restricted stock units and ESPP are recognized in the statements of income based on their fair values.

Employee equity-based compensation pre-tax expense for the three and six months ended March 31, 2026 and 2025 was as follows:

| | Three months ended March 31, | | Six months ended March 31, | |
|-------------------------------------|---------------------------------|------------------|-------------------------------|------------------|
| | 2026 | 2025 | 2026 | 2025 |
| Cost of revenue | \$ 11,392 | \$ 12,356 | \$ 22,765 | \$ 25,606 |
| Research and development | 2,068 | 2,283 | 3,927 | 4,554 |
| Selling, general and administrative | 24,539 | 11,014 | 35,397 | 22,013 |
| Total | <u>\$ 37,999</u> | <u>\$ 25,653</u> | <u>\$ 62,089</u> | <u>\$ 52,173</u> |

The Company recognizes compensation costs for its equity incentive grants using the graded vesting attribution method. As of March 31, 2026, there was \$108,560 of unrecognized compensation expense related to unvested stock options, unvested restricted stock and unvested restricted stock units which is expected to be recognized over a weighted average period of approximately one to two years, based on the vesting periods of the grants.

As of March 31, 2026, there was \$1,542 of unrecognized compensation expense related to the ESPP which is expected to be recognized over the remaining purchase period.

15. Dividends

The Company's Board of Directors declared the following dividends during the six months ended March 31, 2026 and 2025:

| Declaration Date | Dividends Per Ordinary Share | Record Date | Total Amount | Payment Date |
|-------------------|---------------------------------|-------------------|--------------|------------------|
| February 3, 2026 | \$ 0.569 | March 31, 2026 | \$ 60,429 | April 24, 2026 |
| November 11, 2025 | \$ 0.527 | December 31, 2025 | \$ 56,693 | January 30, 2026 |
| February 4, 2025 | \$ 0.527 | March 31, 2025 | \$ 58,615 | April 25, 2025 |
| November 12, 2024 | \$ 0.479 | December 31, 2024 | \$ 53,729 | January 31, 2025 |

The amounts payable as a result of the February 3, 2026 and February 4, 2025 declarations were included in accrued expenses and other current liabilities as of March 31, 2026 and 2025, respectively.

On May 13, 2026 the Company's Board of Directors approved the next quarterly dividend payment and set June 30, 2026 as the record date for determining the shareholders entitled to receive the dividend, which is payable on July 31, 2026.

AMDOCS LIMITED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollar and share amounts in thousands, except per share data or as otherwise disclosed)

16. Segment Information

The Company manages its operations as one operating segment, providing software products and services primarily for the communications and media industry service providers. The Company's Chief Operating Decision Maker ("CODM") is the Company's Chief Executive Officer. The CODM evaluates the operating results of the Company on a consolidated net income basis. Refer to the consolidated statements of income. The financial information is used by the CODM for purposes of making operating decisions, allocating capital and resources, setting budgets, and assessing actual performance relative to these budgets and competitors' information. The Company's significant segment expenses, which are the expenses included in operating income, and other segment items, which include interest and other expense, net and income taxes, are included in the consolidated statements of income. Segment assets provided to the CODM include accounts receivable billed, current and non-current accounts receivable unbilled and current and non-current deferred revenue.

17. Contingencies

Legal Proceedings

The Company is involved in various legal claims and proceedings arising in the normal course of its business. The Company accrues for a loss contingency when it determines that it is probable, after consultation with counsel, that a liability has been incurred and the amount of such loss can be reasonably estimated. At this time, the Company believes that the results of any such contingencies, either individually or in the aggregate, will not have a material adverse effect on the Company's financial position, results of operations or cash flows.

Item 2. Operating and Financial Review and Prospects

Forward Looking Statements

This section contains forward-looking statements (within the meaning of the United States federal securities laws) that involve substantial risks and uncertainties. You can identify these forward-looking statements by words such as “expect,” “anticipate,” “believe,” “seek,” “estimate,” “project,” “forecast,” “continue,” “potential,” “should,” “would,” “could,” “intend” and “may,” and other words that convey uncertainty of future events or outcome. Statements that we make in this document that are not statements of historical fact also may be forward-looking statements. Forward-looking statements are not guarantees of future performance, and involve risks, uncertainties and assumptions that may cause our actual results to differ materially from the expectations that we describe in our forward-looking statements. There may be events in the future that we are not accurately able to predict, or over which we have no control. You should not place undue reliance on forward-looking statements. Although we may elect to update forward-looking statements in the future, we disclaim any obligation to do so, even if our assumptions and projections change, except where applicable law may otherwise require us to do so. Readers should not rely on those forward-looking statements as representing our views as of any date subsequent to the date of this report.

Important factors that may affect these projections or expectations include, but are not limited to: the effects of general macro-economic conditions, prevailing level of macro-economic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on our customers’ businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of our customers. Our ability to grow in the business markets that we serve, our ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render our products and services obsolete, security incidents, including breaches and cyber attacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI (GenAI) in our offerings and operations, and risks associated with operating businesses in the international market. For a discussion of these and other important factors and other risks, please read the information set forth under the caption “Risk Factors” in our Annual Report on Form 20-F for fiscal year 2025, filed on December 15, 2025 with the U.S. Securities and Exchange Commission.

Overview of Business and Trend Information

Amdocs is a leading provider of software and services for approximately 400 communications, entertainment and media industry and other service providers in developed countries and emerging markets. Our software and services, which we develop, implement and manage in a unique accountability model, are designed to meet the business imperatives of our customers, create value for society and make our increasingly connected world more empowering by unlocking our customers’ innovative potential and enabling them to transform their boldest ideas into reality and deliver outstanding customer experiences. Our offerings enable service providers to cost-effectively engage their customers, introduce new products and services, automate service and network operations, monetize connectivity and content, support new business models and generally enhance their understanding of their customers.

We believe the demand for our solutions is driven by our customers’ continued migration to the cloud, deployment of 5G standalone, fixed wireless access (FWA), B2B acceleration, and fiber networks and their transformation into digital service providers to provide connectivity services, content and applications (apps) on any device through digital and non-digital channels. Regardless of whether service providers are bringing their first offerings to market, scaling for growth, consolidating systems or transforming the way they do business, we believe that they seek to differentiate themselves by delivering a customer experience that is simple, personal, contextual and valuable at every point of engagement and across all channels.

Our offerings, grouped by technology capabilities such as commerce and care, monetization, service and network automation, are designed to meet the challenges facing our customers as they roll out 5G, FWA and fiber networks, migrate to the cloud, introduce GenAI solutions and transform into digital service providers within the framework of a hybrid IT environment, which requires them to rapidly introduce new cloud-native applications while still operating legacy systems. Our software is designed to enable modular expansion as a service provider evolves, and its microservices-based architecture enables the rapid deployment of complex applications as suites of independently deployable services that can be frequently upgraded via DevSecOps. Our comprehensive line of services is designed to address every stage of a service provider’s lifecycle. They include consulting, experience design, data, cloud, network services, to delivery, quality engineering (testing), operations, systems integration, and content services. Our managed services provide multi-year, flexible and tailored support, managing IT business processes and applications services. They include application development, modernization and maintenance, IT and infrastructure services, testing and professional services that are designed to assist customers in the selection, implementation, operation, management and maintenance of their IT systems.

We conduct our business globally, and as a result we are subject to the effects of global economic conditions and, in particular, market conditions in the communications and media industry. In the six months ended March 31, 2026, customers in North America accounted for 65.3% of our revenue, while customers in Europe and the rest of the world accounted for 16.0% and 18.7%, respectively. We maintain and support development facilities in Brazil, Canada, Cyprus, India, Ireland, Israel, Mexico, the Philippines, the UK and the United States.

We derive our revenue principally from:

- the initial sales of licenses to use our products and related services, including modification, implementation, integration and customization services,
- providing managed services in our domain expertise and other related services, and
- recurring revenue from ongoing support, maintenance and enhancements provided to our customers, and from incremental license fees resulting from increases in a customer's business volume.

Our results of operations are affected by general economic conditions, including macro-economic conditions, and the level of economic activity in the industries and markets that we serve. In addition, the prevailing level of macro-economic, business, and operational uncertainty, as well as the current inflationary environment and foreign exchange rates fluctuation, may continue to present challenges in future periods and may affect the spending decisions of our customers. Although we try to mitigate the foreign currency exchange rates impact on our results through our hedging policy, we cannot assure that we will be able to effectively limit all of our exposure.

Revenue Recognition, we recognize revenue under the five-step methodology required under ASC 606, which requires us to identify the contract with the customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations identified, and recognize revenue when (or as) each performance obligation is satisfied.

As a significant portion of our revenue is satisfied over time as work progresses, the annual and quarterly operating results may be affected by the size and timing of the initiation of customer projects as well as our progress in completing such projects.

For our primary revenue categories, related performance obligations, and associated recognition patterns please see Note 4 to our consolidated financial statements.

Revenue generated in connection with managed services arrangements is a significant part of our business, generating substantial, long-term recurring revenue streams and cash flow. Managed services arrangements include management of data center operations and IT and cloud infrastructure, application management and ongoing support, management of end-to-end business processes, and managed transformation that includes both a transformation project as well as taking over managed services responsibility. Revenue from managed services arrangements accounted for approximately \$758.7 million and \$747.1 million in the three months ended March 31, 2026 and 2025, respectively, and \$1.50 billion and \$1.48 billion in the six months ended March 31, 2026 and 2025. This is supported by historical renewal rate of close to 100% for our managed services arrangements. Managed services engagements can be less profitable in their early stages; however, margins tend to improve over time, and this improvement is seen more rapidly in the initial period of an engagement, as we derive benefit from the operational efficiencies and from changes in the geographical mix of our resources.

Twelve-month backlog was \$4.28 billion as of March 31, 2026, up approximately 2.6% as compared to March 31, 2025. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities.

Recent Accounting Standards

Please see Note 2 to our consolidated financial statements.

Results of Operations

The following table sets forth our results of operations for the three and six months ended March 31, 2026 and 2025. Certain items in our consolidated statements of income are reflected as a percentage of revenue (figures may not sum because of rounding):

| | Three months ended March 31, | | Six months ended March 31, | |
|---|---------------------------------|--------------|-------------------------------|--------------|
| | 2026 | 2025 | 2026 | 2025 |
| Revenue | 100% | 100% | 100% | 100% |
| Operating expenses: | | | | |
| Cost of revenue | 61.2 | 61.9 | 62.0 | 61.7 |
| Research and development | 7.4 | 7.3 | 7.3 | 7.4 |
| Selling, general and administrative | 13.1 | 11.9 | 11.5 | 11.5 |
| Amortization of purchased intangible assets and other | 1.8 | 1.4 | 1.5 | 1.4 |
| Restructuring charges | 0.9 | — | 0.9 | 0.3 |
| | <u>84.4</u> | <u>82.5</u> | <u>83.3</u> | <u>82.3</u> |
| Operating income | 15.6 | 17.5 | 16.7 | 17.7 |
| Interest and other expense, net | (0.5) | (0.8) | (0.7) | (0.7) |
| Income before income taxes | 15.1 | 16.8 | 16.0 | 17.1 |
| Income taxes | 3.3 | 2.2 | 3.2 | 2.9 |
| Net income | <u>11.8%</u> | <u>14.5%</u> | <u>12.8%</u> | <u>14.1%</u> |
| Net income attributable to noncontrolling interests | 0.08 | 0.07 | 0.08 | 0.07 |
| Net income attributable to Amdocs Limited | <u>11.8%</u> | <u>14.5%</u> | <u>12.7%</u> | <u>14.0%</u> |

Six Months Ended March 31, 2026 and 2025

The following is a tabular presentation of our results of operations for the six months ended March 31, 2026 compared to the six months ended March 31, 2025. Following the table is a discussion and analysis of our business and results of operations for such periods.

| | Six months ended March 31, | | Increase (Decrease) | |
|---|-------------------------------|-------------------|---------------------|---------------|
| | 2026 | 2025 | Amount | % |
| Revenue (*) | \$ 2,327,918 | \$ 2,238,258 | \$ 89,660 | 4.0% |
| Operating expenses: | | | | |
| Cost of revenue | 1,444,456 | 1,380,308 | 64,148 | 4.6 |
| Research and development | 168,979 | 166,129 | 2,850 | 1.7 |
| Selling, general and administrative | 267,398 | 256,712 | 10,686 | 4.2 |
| Amortization of purchased intangible assets and other | 35,842 | 31,757 | 4,085 | 12.9 |
| Restructuring charges | 21,706 | 6,783 | 14,923 | 220.0 |
| | <u>1,938,381</u> | <u>1,841,689</u> | <u>96,692</u> | <u>5.3</u> |
| Operating income | 389,537 | 396,569 | (7,032) | (1.8) |
| Interest and other expense, net | (17,228) | (14,874) | 2,354 | 15.8 |
| Income before income taxes | 372,309 | 381,695 | (9,386) | (2.5) |
| Income taxes | 75,083 | 65,842 | 9,241 | 14.0 |
| Net income | <u>\$ 297,226</u> | <u>\$ 315,853</u> | <u>\$ (18,627)</u> | <u>(5.9)%</u> |
| Net income attributable to noncontrolling interests | 1,845 | 1,477 | 368 | 24.9 |
| Net income attributable to Amdocs Limited | <u>\$ 295,381</u> | <u>\$ 314,376</u> | <u>\$ (18,995)</u> | <u>(6.0)%</u> |

(*) Geographic Information:

| | Six months ended March 31, | | Increase (Decrease) | |
|--------------------------------------|-------------------------------|---------------------|---------------------|-------------|
| | 2026 | 2025 | Amount | % |
| | | | | |
| | | (In thousands) | | |
| North America (mainly United States) | \$ 1,519,006 | \$ 1,475,731 | \$ 43,275 | 2.9% |
| Europe | 373,561 | 335,908 | 37,653 | 11.2 |
| Rest of the world | 435,351 | 426,619 | 8,732 | 2.0 |
| Total | <u>\$ 2,327,918</u> | <u>\$ 2,238,258</u> | <u>\$ 89,660</u> | <u>4.0%</u> |

Revenue. Revenue increased by \$89.7 million, or 4.0%, to \$2,327.9 million in the six months ended March 31, 2026, from \$2,238.3 million in the six months ended March 31, 2025, including approximately 1.2% positive foreign exchange fluctuations impact. The increase in revenue for the six months ended March 31, 2026, was attributable to increased activity across all regions and was positively affected by activities related to recent completed acquisitions.

In the six months ended March 31, 2026, revenue from customers in North America, Europe and the rest of the world accounted for 65.3%, 16.0% and 18.7%, respectively, of total revenue, compared to 65.9%, 15.0% and 19.1%, respectively, in the six months ended March 31, 2025.

Revenue from customers in North America increased in absolute amounts during the six months ended March 31, 2026 compared to the six months ended March 31, 2025, while total revenue increased at a higher rate, which resulted in a decrease of revenue from customers in North America as a percentage of total revenue in the six months ended March 31, 2026. The increase in revenue from customers in North America in absolute amount was primarily attributable to increased activities from some of our key customers in North America.

Revenue from customers in Europe increased during the six months ended March 31, 2026, as we expand managed services and project activities in this region, as well as contribution from the previously completed acquisitions. The increase in revenue in Europe was also positively affected by foreign exchange fluctuations.

Revenue from customers in the rest of the world increased in absolute amounts in the six months ended March 31, 2026, primarily as a result of contribution from the previously completed acquisitions, as well as new activities that continued to ramp up with various customers in Asia Pacific region.

Cost of Revenue. Cost of revenue consists primarily of costs associated with providing services to customers, including compensation expense and costs of third-party products, as well as fee and royalty payments to software suppliers. Cost of revenue increased by \$64.1 million, or 4.6%, to \$1,444.5 million in the six months ended March 31, 2026, from \$1,380.3 million in the six months ended March 31, 2025. The cost of revenue as a percentage of revenue, increased to 62.0% in the six months ended March 31, 2026, from 61.7% in the six months ended March 31, 2025. While the increase in cost of revenue was roughly commensurate with revenue growth, it also includes enhanced investment in AI-based tools, as well as cost of initial customers' GenAI deployments.

Research and Development. Research and development expense is primarily comprised of compensation expense. Research and development expense slightly increased by \$2.9 million, or 1.7%, to \$169.0 million in the six months ended March 31, 2026, from \$166.1 million in the six months ended March 31, 2025. Research and development expense slightly decreased as a percentage of total revenue from 7.4% in the six months ended March 31, 2025, to 7.3% in the six months ended March 31, 2026, as total revenue increased at a higher rate than research and development expense. We continue to invest in AI and GenAI capabilities, and in our cloud offerings, network related innovation, and further developing our digital offerings. Our research and development efforts are a key element of our strategy and are essential to our success, and we intend to maintain our commitment to research and development. However, increase or decrease in our revenue would not necessarily result in a proportional increase or decrease in the levels of our research and development expenditures, which could affect our operating margin.

Selling, General and Administrative. Selling, general and administrative expense, which is primarily comprised of compensation expense, increased by \$10.7 million, or 4.2%, to \$267.4 million in the six months ended March 31, 2026, from \$256.7 million in the six months ended March 31, 2025. Selling, general and administrative expense as a percentage of total revenue was 11.5% in the six months ended March 31, 2026 and 2025. Selling, general and administrative expense may fluctuate from time to time, depending upon such factors as changes in our workforce and sales efforts and the results of any operational efficiency programs that we may undertake. The increase in absolute amount was primarily attributable to an increase in equity based compensation expense, changes of certain acquisition-related liabilities measured at fair value, partially offset by a decrease in account receivable allowances.

Amortization of Purchased Intangible Assets and Other. Amortization of purchased intangible assets and other in the six months ended March 31, 2026, increased by \$4.1 million, or 12.9% to \$35.8 million from \$31.8 million in the six months ended March 31, 2025. The increase in amortization of purchased intangible assets and other was primarily attributable to an increase in amortization of intangible assets due to recent completed acquisitions, partially offset by a decrease in amortization of previously purchased intangible assets.

Restructuring Charges. Restructuring charges for the six months ended March 31, 2026, were \$21.7 million, and were \$6.8 in the six months ended March 31, 2025. Further to our restructuring activities in prior fiscal years, we have undertaken certain additional restructuring actions to focus on operational excellence, automation and the internal deployment of GenAI based tools across our operations. We continue to evaluate further operational efficiencies. For the restructuring charges for the comparable period and for more details, please see Note 9 to our consolidated financial statements.

Operating Income. Operating income decreased by \$7.0 million, or 1.8%, in the six months ended March 31, 2026, to \$389.5 million, from \$396.6 million, in the six months ended March 31, 2025. Operating income decreased as a percentage of revenue from 17.7% in the six months ended March 31, 2025, to 16.7% in the six months ended March 31, 2026. The decrease in operating income as a percentage of revenue was primarily attributable to relatively higher level of restructuring charges recognized in the six months ended March 31, 2026, compared to the six months ended March 31, 2025, and to an increase in cost of revenue. The foreign exchange impacts on our operating income were immaterial.

Interest and Other Expense, Net. Interest and other expense, net, increased from a net expense of \$14.9 million in the six months ended March 31, 2025, to a net expense of \$17.2 million in the six months ended March 31, 2026. The increase in interest and other expense, net, was primarily attributable to an increase in interest expenses net of interest income, as a result of lower level of cash balances and higher short-term borrowing, partially offset by net gains related to equity investments, and a decrease in foreign exchange fluctuation charges.

Income Tax expense. Income tax expense for the six months ended March 31, 2026 were \$75.1, million, on pre-tax income of \$372.3 million, resulting in an effective tax rate of 20.2%, compared to 17.2% in the six months ended March 31, 2025. Please see also Note 10 to our consolidated financial statements. Our effective tax rate may fluctuate between periods as a result of discrete items that may affect a particular period.

Net income attributable to Amdocs Limited. Net income decreased by \$19.0 million, or 6.0%, to \$295.4 million in the six months ended March 31, 2026, from \$314.4 million in the six months ended March 31, 2025. The decrease in net income is primarily attributable a decrease in operating income and an increase in income tax expense.

Diluted Earnings Per Share. Diluted earnings per share decreased by \$0.04, or 1.4%, to \$2.74 in the six months ended March 31, 2026, from \$2.78 in the six months ended March 31, 2025. The decrease in diluted earnings per share was primarily attributable to decrease in net income in the six months ended March 31, 2026, partially offset by a decrease in the diluted weighted average number of shares outstanding which resulted from share repurchases. Please see also Note 11 to our consolidated financial statements.

Three Months Ended March 31, 2026 and 2025

The following is a tabular presentation of our results of operations for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. Following the table is a discussion and analysis of our business and results of operations for such periods.

| | Three months ended March 31, | | Increase (Decrease) | |
|---|---------------------------------|--------------|---------------------|---------|
| | 2026 | 2025 | Amount | % |
| | (in thousands) | | | |
| Revenue (*) | \$ 1,171,979 | \$ 1,128,203 | \$ 43,776 | 3.9% |
| Operating expenses: | | | | |
| Cost of revenue | 716,733 | 698,049 | 18,684 | 2.7 |
| Research and development | 87,001 | 81,796 | 5,205 | 6.4 |
| Selling, general and administrative | 153,677 | 134,625 | 19,052 | 14.2 |
| Amortization of purchased intangible assets and other | 21,308 | 15,998 | 5,310 | 33.2 |
| Restructuring charges | 10,405 | — | 10,405 | 100.0 |
| | 989,124 | 930,468 | 58,656 | 6.3 |
| Operating income | 182,855 | 197,735 | (14,880) | (7.5) |
| Interest and other expense, net | (5,963) | (8,465) | (2,502) | (29.6) |
| Income before income taxes | 176,892 | 189,270 | (12,378) | (6.5) |
| Income taxes | 38,120 | 25,269 | 12,851 | 50.9 |
| Net income | \$ 138,772 | \$ 164,001 | \$ (25,229) | (15.4)% |
| Net income attributable to noncontrolling interests | 957 | 758 | 199 | 0.3 |
| Net income attributable to Amdocs Limited | \$ 137,815 | \$ 163,243 | \$ (25,428) | (15.6)% |

(*) Geographic Information:

| | Three months ended March 31, | | (Decrease) Increase | |
|--------------------------------------|---------------------------------|---------------------|---------------------|-------------|
| | 2026 | 2025 | Amount | % |
| | (In thousands) | | | |
| North America (mainly United States) | \$ 754,305 | \$ 738,335 | \$ 15,970 | 2.2% |
| Europe | 191,832 | 180,676 | 11,156 | 6.2 |
| Rest of the world | 225,842 | 209,192 | 16,650 | 8.0 |
| Total | <u>\$ 1,171,979</u> | <u>\$ 1,128,203</u> | <u>\$ 43,776</u> | <u>3.9%</u> |

Revenue. Revenue increased by \$43.8 million, or 3.9%, to \$1,172.0 million in the three months ended March 31, 2026, from \$1,128.2 million in the three months ended March 31, 2025 including approximately 1.7% positive foreign exchange fluctuations impact. The increase in revenue for the three months ended March 31, 2026, was attributable to increased activity across all regions, and was positively affected by activities related to recent completed acquisitions.

In the three months ended March 31, 2026, revenue from customers in North America, Europe and the rest of the world accounted for 64.4%, 16.3% and 19.3%, respectively, of total revenue, compared to 65.4%, 16.0% and 18.6%, respectively, in the three months ended March 31, 2025.

Revenue from customers in North America increased in absolute amounts during the three months ended March 31, 2026, while total revenue increased at a higher rate, which resulted in a decrease of revenue from customers in North America as a percentage of total revenue in the three months ended March 31, 2026. The increase in revenue from customers in North America in absolute amount was primarily attributable to increased activities from some of our key customers in North America.

Revenue from customers in Europe increased during the three months ended March 31, 2026, is primarily attributable to new acquisitions activities mentioned above, as well as positive foreign exchange fluctuation.

Revenue from customers in the rest of the world increased during the three months ended March 31, 2026, primarily as a result of contribution from the previously completed acquisitions, as well as new activities that continued to ramp up with various customers in Asia Pacific region.

Cost of Revenue. Cost of revenue consists primarily of costs associated with providing services to customers, including compensation expense and costs of third-party products, as well as fee and royalty payments to software suppliers. Cost of revenue increased by \$18.7 million, or 2.7%, to \$716.7 million in the three months ended March 31, 2026, from \$698.0 million in the three months ended March 31, 2025. The cost of revenue as a percentage of revenue decreased to 61.2% in the three months ended March 31, 2026, from 61.9% in the three months ended March 31, 2025. The cost of revenue also includes enhanced investment in AI-based tools, as well as cost of initial customers' GenAI deployments.

Research and Development. Research and development expense is primarily comprised of compensation expense. Research and development expense increased by \$5.2 million, or 6.4%, to \$87.0 million in the three months ended March 31, 2026, from \$81.8 million in the three months ended March 31, 2025. Research and development expense slightly increased as a percentage of total revenue from 7.3% in the three months ended March 31, 2025, to 7.4% in the three months ended March 31, 2026 and includes contribution of recent completed acquisitions. We continue to invest in AI and GenAI capabilities, and in our cloud offerings, network related innovation, and further developing our digital offerings. Our research and development efforts are a key element of our strategy and are essential to our success, and we intend to maintain our commitment to research and development. However, increase or decrease in our revenue would not necessarily result in a proportional increase or decrease in the levels of our research and development expenditures, which could affect our operating margin.

Selling, General and Administrative. Selling, general and administrative expense, which is primarily comprised of compensation expense, increased in absolute amounts by \$19.1 million, or 14.2%, to \$153.7 million in the three months ended March 31, 2026, from \$134.6 million in the three months ended March 31, 2025. Selling, general and administrative expense increased as a percentage of revenue from 11.9% in the three months ended March 31, 2025, to 13.1% in the three months ended March 31, 2026. The increase in was primarily attributable to an increase in equity based compensation expense and to a lesser extent an increase in account receivable allowances. Selling, general and administrative expense may fluctuate from time to time, depending upon such factors as changes in our workforce and sales efforts and the results of any operational efficiency programs that we may undertake.

Amortization of Purchased Intangible Assets and Other. Amortization of purchased intangible assets and other in the three months ended March 31, 2026, increased by \$5.3 million, or 33.2% to \$21.3 million from \$16.0 million in the three months ended March 31, 2025. The increase in amortization of purchased intangible assets and other was an increase in amortization of intangible assets due to recent completed acquisitions, partially offset by a decrease in amortization of previously purchased intangible assets.

Restructuring Charges. Restructuring charges for the three months ended March 31, 2026, were \$10.4, while there were no such restructuring charges in the three months ended March 31, 2025. Further to our restructuring activities in prior fiscal years, we have undertaken certain additional restructuring actions to focus on operational excellence, automation and the internal deployment of GenAI based tools across our operations. We continue to evaluate further operational efficiencies. For the restructuring charges for the comparable period and for more details, please see Note 9 to our consolidated financial statements.

Operating Income. Operating income decreased by \$14.9 million, or 7.5%, in the three months ended March 31, 2026, to \$182.9 million, or 15.6% of revenue, from \$197.7 million, or 17.5% of revenue, in the three months ended March 31, 2025. The decrease in operating income as a percentage of revenue was primarily attributable to increase in (i) selling, general and administrative expense, (ii) restructuring charges recorded in the three months ended March 31, 2026, while there were no such charges in the three months ended March 31, 2025, partially offset by decrease in cost of revenue. The foreign exchange impacts on our operating income were immaterial.

Interest and Other Expense, Net. Interest and other expense, net, decreased from a net expense of \$8.5 million in the three months ended March 31, 2025 to a net expense of \$6.0 million in the three months ended March 31, 2026. The decrease in interest and other expense, net, was primarily attributable to net gains related to equity investments resulting in a net decrease of \$7.1 million compared to the three months ended March 31, 2025, partially offset by an increase in interest expenses net of interest income, as a result of lower level of cash balances and higher short-term borrowing, as well as an increase in foreign exchange fluctuation charges.

Income Tax expense. Income tax expense for the three months ended March 31, 2026 were \$38.1 million on pre-tax income of \$176.9 million, resulting in an effective tax rate of 21.5%, compared to effective tax rate of 13.4% in the three months ended March 31, 2025. Our effective tax rate may fluctuate between periods as a result of discrete items that may affect a particular period, please see Note 10 to our consolidated financial statements.

Net income attributable to Amdocs Limited. Net income decreased by \$25.4 million, or 15.6%, to \$137.8 million in the three months ended March 31, 2026, from \$163.2 million in the three months ended March 31, 2025. The decrease in net income is primarily attributable to a decrease in operating income, and an increase in income tax expense, in the three months ended March 31, 2026 compared to the three months ended March 31, 2025.

Diluted Earnings Per Share. Diluted earnings per share decreased by \$0.17, or 11.7%, to \$1.28 in the three months ended March 31, 2026, from \$1.45 in the three months ended March 31, 2025. The decrease in diluted earnings per share was primarily attributable to a decrease in net income in the three months ended March 31, 2026, partially offset by a decrease in the diluted weighted average number of shares outstanding which resulted from share repurchases. Please see also Note 11 to our consolidated financial statements.

Liquidity and Capital Resources

Cash and Cash Equivalents. Cash, cash equivalents, totaled \$214.5 million as of March 31, 2026, compared to \$325.0 million as of September 30, 2025. The decrease was mainly attributable to \$284.5 million repurchase of our ordinary shares pursuant to our repurchase program, \$217.7 million payments for business acquisitions, \$113.8 million of cash dividend payment, \$25.9 million deferred payments of business acquisitions and \$53.5 million for capital expenditures, net, partially offset by \$321.8 million positive cash flow from operating activities, \$250 million borrowing under short-term financing arrangements, \$11.8 million net proceeds from equity investments and other and \$3.2 million of proceeds from stock options. Net cash provided by operating activities amounted to \$321.8 million and \$278.0 million in the six months ended March 31, 2026 and 2025, respectively.

Our free cash flow for the six months ended March 31, 2026 was \$268.3 million and is calculated as net cash provided by operating activities of \$321.8 million for the period less \$53.5 million for capital expenditures, net, and is after restructuring payments of approximately \$66 million.

Free cash flow is a non-GAAP financial measure and is not prepared in accordance with, and is not an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures with similar names used by other companies. Non-GAAP measures such as free cash flow should only be reviewed in conjunction with the corresponding GAAP measures. We believe that free cash flow, when used in conjunction with the corresponding GAAP measure, provides useful information to investors and management relating to the amount of cash generated by the Company's business operations.

We believe that our current cash balances, cash generated from operations, our current lines of credit, commercial paper, loans, Senior Notes and our ability to access capital markets serve as sources of liquidity if needed and will provide sufficient resources to meet our operational needs, loan and debt repayment needs, fund share repurchases and the payment of cash dividends for at least the next twelve months.

We have short-term interest-bearing investments comprised of marketable securities and bank deposits. We classify all of our marketable securities as available-for-sale securities. Such marketable securities consist primarily of money market funds, which are stated at market value and are classified as cash and cash equivalents.

We believe we have conservative investment policy guidelines. Our interest-bearing investments are stated at fair value with the unrealized gains or losses, if applicable, reported as a separate component of accumulated other comprehensive (loss) income, net of tax, unless a security is impaired due to a credit loss, in which case the loss is recorded in the consolidated statements of income. Our interest-bearing investments are priced by pricing vendors and are classified as Level 1, since these vendors either provide a quoted market price in an active market or use other observable inputs to price these securities. During the six months ended March 31, 2026 and 2025, we did not recognize any credit losses. Please see Notes 5 and 6 to the consolidated financial statements.

Revolving Credit Facility, Commercial Paper, Loans, Senior Notes, Letters of Credit, Guarantees and Contractual Obligations. In December 2011, we entered into the unsecured \$500.0 million Revolving Credit Facility. In December 2014, December 2017, March 2021 and July 2024, the Revolving Credit Facility was amended and restated to, among other things, extend the maturity date of the facility to December 2019, December 2022, March 2026 and July 2029, respectively. In March 2026 the Revolving Credit Facility was amended to increase the amount from \$500.0 million to an aggregate amount of \$800.0 million. As of March 31, 2026, we were in compliance with the financial covenants and had \$170.0 million outstanding borrowing under the Revolving Credit Facility, as a result, \$630.0 million remains available on the Revolving Credit Facility.

In March 2026, we established a commercial paper program, supported by the Revolving Credit Facility under which it may issue unsecured commercial paper up to a total of \$800.0 million outstanding at any time, with maturities of up to 397 days from the date of issue. The net proceeds from the issuance of commercial paper are expected to be used for general corporate purposes. As of March 31, 2026, there was no outstanding borrowing amount under the commercial paper program.

In June 2020, we issued an aggregate principal amount of \$650.0 million in Senior Notes that will mature in June 2030 and bear interest at a fixed rate of 2.538 percent per annum (the "Senior Notes"). The interest is payable semi-annually in June and December of each year, commencing in December 2020. We incurred issuance costs of \$6.1 million in relation to the Senior Notes, which are being amortized to interest expenses over the term of the Senior Notes using the effective interest rate. The Senior Notes are senior unsecured obligations and rank equally in right of payment with all of our existing and future senior indebtedness, including any indebtedness we may incur from time to time under the Revolving Credit Facility. As of March 31, 2026, the noncurrent outstanding principal portion was \$650.0 million. Please see Note 13 to our consolidated financial statements.

As of March 31, 2026, we had additional uncommitted lines of credit available for general corporate and other specific purposes and had \$80.0 million outstanding borrowing under the uncommitted lines of credit. We had outstanding letters of credit and bank guarantees from various banks totaling \$90.7 million as of March 31, 2026, which were supported by a combination of the uncommitted lines of credit that we maintain with various banks.

We have contractual obligations for Long-term debt and accrued interests, operating leases, purchase obligations, pension funding and unrecognized tax benefits, summarized in the disclosure of contractual obligations set forth in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025 with the SEC. During the three months ended December 31, 2025, we renewed our framework agreement with a strategic cloud provider, encompassing a commitment by us for service usage (including cloud consumption) totaling \$570.0 million for five years.

Acquisitions. During the six months ended March 31, 2026, we completed two business acquisitions for an aggregate net consideration of approximately \$217.0. The majority of this amount was paid to the acquisition of Matrixx Software, a privately owned company specializing in Charging & Rating solutions for global communication service providers, please see Note 3 to our consolidated financial statements.

Capital Expenditures. Generally, the majority of our capital expenditures consist of purchases of computer, related equipment and software, and the remainder is attributable mainly to building and leasehold improvements. Our capital expenditures were approximately \$53.5 million in the six months ended March 31, 2026 and were mainly attributable to investments in our operating facilities and our development centers around the world.

Share Repurchases. From time to time, our Board of Directors can adopt share repurchase plans authorizing the repurchase of our outstanding ordinary shares. On May 7, 2025, our Board of Directors adopted a share repurchase plan for the repurchase of up to an additional \$1.0 billion of our outstanding ordinary shares with no expiration date. The May 2025 plan permits us to purchase our ordinary shares in the open market or through privately negotiated transactions at times and prices that we consider appropriate. In the six months ended March 31, 2026 we repurchased 3.8 million ordinary shares at an average price of \$75.78 per share (excluding broker and transaction fees). As of March 31, 2026, we had remaining authority to repurchase up to \$701.9 million of our outstanding ordinary shares under the May 2025 plan.

Cash Dividends. Our Board of Directors declared the following dividends during the six months ended March 31, 2026 and 2025:

| Declaration Date | Dividends Per Ordinary Share | Record Date | Total Amount in millions | Payment Date |
|-------------------------|-------------------------------------|--------------------|---------------------------------|---------------------|
| February 3, 2026 | \$ 0.569 | March 31, 2026 | \$ 60.4 | April 24, 2026 |
| November 11, 2025 | \$ 0.527 | December 31, 2025 | \$ 56.7 | January 30, 2026 |
| February 4, 2025 | \$ 0.527 | March 31, 2025 | \$ 58.6 | April 25, 2025 |
| November 12, 2024 | \$ 0.479 | December 31, 2024 | \$ 53.7 | January 31, 2025 |

On May 13, 2026 our Board of Directors approved the next quarterly dividend payment and set June 30, 2026 as the record date for determining the shareholders entitled to receive the dividend, which is payable on July 31, 2026.

Our Board of Directors considers on a quarterly basis whether to declare and pay, if any, a dividend in accordance with the terms of the dividend program, subject to applicable Guernsey law and based on several factors including our financial performance, outlook and liquidity. Guernsey law requires that our Board of Directors considers a dividend's effects on our solvency before it may be declared or paid. While the Board of Directors will have the authority to reduce the quarterly dividend or discontinue the dividend program should it determine that doing so is in the best interests of our shareholders or is necessary pursuant to Guernsey law, any increase to the per share amount or frequency of the dividend would require shareholder approval.

Currency Fluctuations

We manage our foreign subsidiaries as integral direct components of our operations. The operations of our foreign subsidiaries provide the same type of services with the same type of expenditure throughout the Amdocs group. The U.S. dollar is our functional currency according to the salient economic factors as indicated in the authoritative guidance for foreign currency matters. We periodically assess the applicability of the U.S. dollar as our functional currency by reviewing the salient indicators.

During the six months ended March 31, 2026 and 2025, approximately 70% to 80% of our revenue and approximately 50% to 60% of our operating expenses were in U.S. dollars or linked to the U.S. dollar. If more customers seek contracts in currencies other than the U.S. dollar and as our operational activities outside of the United States may increase, the percentage of our revenue and operating expenses in U.S. dollar or linked to the U.S. dollar may decrease over time, which may increase our exposure to fluctuations in currency exchange rates. In managing our foreign exchange risk, we enter from time to time into various foreign exchange hedging contracts. We do not hedge all of our exposure in currencies other than the U.S. dollar, but rather our policy is to hedge significant net exposures in the major foreign currencies in which we operate, when cost-effective.

PART II OTHER INFORMATION

Item 1. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities.

Ordinary Shares

The following table provides information about purchases by us and our affiliated purchasers during the three months ended March 31, 2026 of equity securities that are registered by us pursuant to Section 12 of the Exchange Act:

| Period | Total Number of Shares Purchased | Average Price Paid per Share(1) | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs(2) |
|-------------------|----------------------------------|---------------------------------|--|---|
| 01/01/26-01/31/26 | 363,639 | \$ 82.50 | 363,639 | \$ 810,258,849 |
| 02/01/26-02/28/26 | 783,349 | \$ 73.24 | 783,349 | \$ 752,885,137 |
| 03/01/26-03/31/26 | 774,865 | \$ 65.74 | 774,865 | \$ 701,942,539 |
| Total | 1,921,853 | \$ 71.97 | 1,921,853 | \$ 701,942,539 |

(1) Excludes broker and transaction fees.

(2) On May 7, 2025, our Board of Directors adopted a share repurchase plan for the repurchase of up to an additional \$1.0 billion of our outstanding ordinary shares with no expiration date. The May 2025 plan permits us to purchase our ordinary shares in the open market or through privately negotiated transactions at times and prices that we consider appropriate.

Item 2. Reports on Form 6-K

The Company furnished or filed the following reports on Form 6-K during the three months ended March 31, 2026:

- (1) Form 6-K dated March 23, 2026
- (2) Form 6-K dated February 17, 2026
- (3) Form 6-K dated February 4, 2026
- (4) Form 6-K dated January 30, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMDOCS LIMITED

/s/ Matthew E. Smith

Matthew E. Smith

Secretary and Authorized Signatory

Date: May 26, 2026